What Is MASLD?

Metabolic dysfunction-associated steatotic liver disease (MASLD) — previously known as non-alcoholic fatty liver disease (NAFLD) — is the most common liver disease worldwide, affecting approximately 25-30% of the global adult population. It ranges from simple fat accumulation in the liver (steatosis) to inflammatory steatohepatitis (MASH, formerly NASH) that can progress to fibrosis, cirrhosis, and liver failure.

For years, MASLD was considered a consequence of obesity and poor diet. While metabolic factors are central, the gut microbiome has emerged as a critical driver of both disease initiation and progression through the gut-liver axis.

The Gut-Liver Axis

The liver and the gut are intimately connected. The portal vein delivers blood directly from the intestine to the liver, meaning that everything absorbed from the gut — nutrients, bacterial metabolites, endotoxins — passes through the liver first. In a healthy state, the gut barrier prevents harmful substances from reaching the liver. When the barrier is compromised, the liver becomes the first organ to bear the consequences.

How Gut Dysbiosis Promotes Fatty Liver

Multiple mechanisms link the gut microbiome to MASLD development:

  • Increased intestinal permeability — a leaky gut allows bacterial LPS to reach the liver via the portal vein, activating hepatic Kupffer cells and stellate cells that drive inflammation and fibrosis
  • Altered bile acid metabolism — gut bacteria convert primary to secondary bile acids, which regulate fat metabolism in the liver through FXR signalling. Dysbiotic microbiomes produce altered bile acid profiles that promote hepatic fat accumulation
  • Ethanol production — certain gut bacteria, particularly Klebsiella pneumoniae, can produce significant amounts of endogenous ethanol through carbohydrate fermentation. This internally produced alcohol is delivered directly to the liver, causing damage identical to alcoholic liver disease
  • Choline deficiency — gut bacteria can deplete dietary choline by converting it to trimethylamine. Choline is essential for very-low-density lipoprotein (VLDL) assembly, which exports fat from the liver. When choline is depleted, fat accumulates in hepatocytes
  • Reduced SCFA production — short-chain fatty acids activate AMPK and PPARalpha in the liver, promoting fat oxidation. Reduced SCFA production shifts hepatic metabolism toward fat storage
Up to 40% of MASLD patients have detectable bacterial overgrowth in the small intestine. SIBO may be both a cause and a consequence of fatty liver disease, as impaired bile flow from a fatty liver promotes bacterial overgrowth in the small intestine.

Microbiome Signatures in MASLD

Large-scale metagenomic studies have identified consistent microbial signatures in MASLD patients:

  • Increased Escherichia coli and Klebsiella pneumoniae (ethanol-producing and LPS-rich species)
  • Reduced Faecalibacterium prausnitzii and other butyrate producers
  • Altered Bacteroides composition affecting bile acid metabolism
  • Increased Ruminococcus species associated with fibrosis progression
  • Overall reduced microbial diversity

Remarkably, microbiome composition can now be used to distinguish simple steatosis from MASH and even to predict fibrosis stage, suggesting that microbial signatures may serve as non-invasive diagnostic biomarkers.

Addressing MASLD Through the Gut

Dietary Interventions

The Mediterranean diet has the strongest evidence for MASLD management and works partly through microbiome modulation. Its emphasis on olive oil, fatty fish, vegetables, legumes, and whole grains promotes microbial diversity, increases SCFA production, and provides polyphenols that support gut barrier integrity. A 2024 meta-analysis showed that the Mediterranean diet reduced hepatic fat by 25-30% over 12 months.

Prebiotic and Probiotic Strategies

Clinical trials have shown that specific probiotic strains (particularly Lactobacillus and Bifidobacterium combinations) reduce liver fat content, lower ALT levels, and decrease inflammatory markers in MASLD patients. Prebiotics including inulin and fructo-oligosaccharides improve the microbial landscape by feeding beneficial bacteria that compete with ethanol-producing and LPS-generating species.

Addressing SIBO

For MASLD patients with concurrent small intestinal bacterial overgrowth, treating SIBO can reduce the bacterial endotoxin load reaching the liver and improve hepatic inflammation. This is an often-overlooked aspect of fatty liver management.

The gut-liver axis makes fatty liver disease as much a gut condition as a liver condition. GutIQ evaluates digestive function, microbiome-related symptoms, and inflammatory patterns that may be contributing to liver health issues, providing insights that complement standard hepatological assessment.